Basiliximab
Astrocytoma, Grade IV
Mustafa Khasraw, MBChB, MD, FRCP, FRACPmonoclonal_antibodyPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Astrocytoma, Grade IV cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Safusidenib Nuvation Bio Inc. | Phase 3 | B |
pp65-flLAMP DC University of Florida | Phase 2 | B |
Peripheral Blood Mononuclear Cell University of Florida | Phase 2 | B |
Olutasidenib Rigel Pharmaceuticals | Phase 2 | CCC |
VOXTALISIB Sanofi | Phase 1 | CCC |
View all 10 →
Same molecule, other indications
Basiliximab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →